Organic Active Ingredients TRIZ Cases

Formulations eliminate binders and structure-forming substances to resolve the contradiction between tablet structural integrity and high omega-3 concentration.

Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones inhibit protein kinases with high potency.

Pyrazolo[1,5-a]pyrimidine derivatives resolve selectivity trade-offs in CDK inhibition by targeting specific isoforms like CDK2 and CDK4 for cancer therapy.

Nitromethylaryl quaternary ammonium salts inhibit EGFR phosphorylation to overcome resistance from T790M and exon 20 insertion mutations.

Alkoxy pyrazoles target oxidized heme iron in soluble guanylate cyclase, restoring enzyme function when nitric oxide signaling fails.

Combines CAR T-cell therapy with BCL2 inhibitors to overcome resistance in high-grade B-cell lymphomas by targeting elevated MYC, BCL2, or BCL6 activity.

Piperazine derivatives inhibit ArfGAP1 to mitigate LRRK2 neurotoxicity in Parkinson's disease.

Covalent chelation anchors zinc or copper ions to porous matrices, preventing diffusion while reducing microbial contamination.

Defined weight ratios of leucine, arginine, glutamine, and NAC treat non-alcoholic steatohepatitis by decreasing pathological tissue damage.

Heat-killed mycobacterium stimulates anti-tumor immunity without chemotherapy toxicity, improving survival in patients with poor performance status.

Segmented methotrexate pellets bypass saturation kinetics to maintain dose-proportional bioavailability while minimizing side effects.

Aluminum particles form a tissue depot for sustained release of TLR7 agonists.

Ophthalmic preparation containing (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine suppresses neovascularization.

Oxy-fluoropiperidine derivatives inhibit JAK3 and BTK enzymes to resolve stability issues and reduce side effects in inflammatory disease treatments.

Segmented excipient matrices enable fast mucosal absorption of lower estrogen doses, resolving the trade-off between efficacy and side effects.

A dietary emulsion formulation combines medium chain triglycerides with very long chain omega-3 fatty acids to provide essential nutrients.

Vacuum distillation extracts camphor from chamomile to produce hydrosol that promotes fibroblast proliferation and migration.

A PRMT4 inhibitor composition reduces protein levels to improve neurovascular coupling in the brain.

Targeted ncRNA biomarkers resolve epithelial tumor specificity issues by identifying unique molecular signatures in accessible biological fluids.

Small molecule inhibitors block HIF prolyl hydroxylase activity, stabilizing HIF-alpha and stimulating endogenous erythropoietin synthesis.

Thiazolopyrimidine derivatives inhibit HIV-1 reverse transcriptase to overcome rapid drug resistance in wild-type and mutant strains.

Tricyclic GPR40 agonists improve glucose and lipid metabolism while reducing hypoglycemia risk in Type 2 diabetes treatment.

Formula I heterocyclic compounds inhibit glutaminase 1 activity, resolving formulation complexity while disrupting cancer cell metabolism.

A microRNA-486 composition with minerals regulates profiles to promote healing.

Tributyrin prodrugs bypass upper GI absorption to deliver butyrate locally, overcoming indiscriminate bacterial stimulation.

A dimethylphosphine oxide compound acts as a potent LRRK2 kinase inhibitor with superior pharmacokinetic properties.

Luteolin-7-O-glucoside resists cardiac fibrosis and ventricular wall thickening, addressing unconfirmed efficacy of conventional statins.

Specific amino acid substitutions and phenylboronic acid stabilize cocaine esterase, resolving the trade-off between enzyme durability and detoxification speed.

Substituted aromatic compounds targeting the HCV NS5A phosphoprotein reduce viral activity in drug-resistant cases.

Pinus lignocellulose binds iron ions to enhance Magnolia antimicrobial efficacy, lowering active ingredient dosage while maintaining growth promotion.

A segmented process synthesizes benzoxazepin oxazolidinone compounds using EDC/HOSu peptide coupling and copper-catalyzed C-N reactions.

Cyclic dinucleotide compounds activate pattern recognition receptors to induce host immune responses against viral infections.

Dispersing a water-immiscible oil phase in an aqueous surfactant matrix stabilizes hydrophobic APIs and reduces application time for treating scalp conditions.

Aza-epoxy guaiane derivatives inhibit tumor growth and metastasis through specific molecular structures.

Conjugating a bifunctional protein degrader with a fatty acid extends serum half-life and reduces clearance rates.

Non-reactive acrylic polymers in a flexible matrix prevent drug degradation and tight release during transdermal delivery.

A biphasic transdermal iontophoretic system uses alternating electrical currents to transport therapeutic agents through the skin.

Lipoic acid derivatives replace impractical mechanical preconditioning by activating Akt kinase to reduce myocardial infarct size.

New PDE4 inhibitor treats inflammatory skin diseases by enhancing penetration and degradability to reduce side effects.

Inhibiting RPL13A snoRNAs via antisense oligonucleotides reduces ROS production, preventing vaso-occlusion and organ damage in sickle cell disease.

A pharmaceutical composition containing 1,5-O-dicaffeoylquinic acid increases tear secretion and reduces corneal epithelial defects.

A heterocyclic compound inhibits cholesterol 24-hydroxylase activity.

A purified eicosapentaenoic acid ethyl ester composition increases plasma EPA levels to treat cardiovascular disease.

Novel imidazolidinonyl aminopyrimidine compounds inhibit Plk1 with improved pharmacokinetic properties.

Enriched gamma delta T cell compositions address short-lived immunity by inducing durable coronavirus-specific cellular and humoral responses.

Azaindole modulators restore CFTR protein folding accuracy, enabling proper ion transport across epithelial tissues.

PDE-9 inhibition overcomes ineffective conventional obesity treatments by targeting deficient nitric oxide signaling pathways.